SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigals strong quarterly Rezdiffra growth and first profitable quarter were followed by a sharp share-price selloff, prompting traders to question why the stock fell despite the results. Bulls point to growing adoption and profitability, while skeptics focus on spending, reimbursement and the need for longer-term clinical outcomes evidence.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Record quarterly results, a raised fiscal-year outlook, and strong bookings tied to AI-chip testing demand are driving AEHRs sharp rally. Traders are upbeat about the growth outlook, while others question the valuation and whether the post-earnings gap can hold.

Backblaze, Inc. operates as a cloud provider for businesses and consumers to store, use, and protect their data. The firm provides a foundation for businesses, developers, IT professionals, and individuals to store, backup, and archive data, host content, manage media, and build their applications. It also offers B2 Cloud Storage and Computer Backup services. The company was founded by Timothy Nufire, Gleb Budman, Charles Jones, Kwok Hang Ng, Brian Wilson, Nilay Patel and Damon Uyeda in 2007 and is headquartered in San Francisco, CA.

Backblaze Inc - Ordinary Shares - Class A

Backblazes Q3 results and raised full-year outlook, led by accelerating B2 cloud-storage growth tied to AI workloads, sparked a sharp rally and are the main focus. Traders are divided after the move faded: bulls see the pullback as an opportunity, while bears point to weak free cash flow and declining legacy backup revenue.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopifys third-quarter results fell short of expectations on gross merchandise volume and subscription metrics, prompting a sharp selloff despite an earnings beat and continued revenue growth. Traders are split between viewing the drop as an overreaction and buying the rebound, and worrying that slowing growth and a rich valuation leave little room for misses.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv shares are rallying after a quarterly earnings beat, reaffirmed outlook, a doubled cost-savings goal, and plans to resume share repurchases. Traders are treating the update as a possible turnaround signal after a prolonged slide, while some remain cautious about weak segments and margin pressure.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Heavy selling ahead of ADMAs scheduled Q3 earnings report is driving discussion, with traders speculating about a possible results leak, major-holder selling, or renewed short pressure; none of those explanations is confirmed. The community is split between viewing the decline as a warning sign and treating it as a possible shakeout, with earnings seen as a key test of the growth story.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers third-quarter results beat expectations and lifted its full-year outlook, driving much of the discussion as traders weigh stronger non-COVID product growth and cost cuts against flat overall revenue and ongoing COVID-product declines. The reaction is divided: some see evidence of a turnaround, while others question whether the guidance raise can overcome patent-cliff concerns and the stocks muted response to the report.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva- Pharmaceutical Industries Ltd.

Teva- Pharmaceutical Industries Ltd. - ADR

Tevas quarterly earnings beat and raised full-year outlook are drawing attention, with traders emphasizing growth in its innovative brands as generics remain under pressure. The reaction is broadly bullish, with shares reaching a fresh 52-week high, though some discussion notes the decline in generics revenue.

Toast, Inc. engages in the development and provision of consumer payment application for restaurants. It offers terminals, kiosk, guest facing display, and system accessories. The firm also offers point of sale, reporting and analytics, online ordering and delivery, and kitchen display system. The company was founded by Jonathan Grimm, Aman Narang, and Stephen J. Fredette in December 2011 and is headquartered in Boston, MA.

Toast Inc - Ordinary Shares - Class A

Toast Inc

Toasts post-earnings selloff is drawing attention despite a reported earnings beat and raised guidance, as traders question whether results were strong enough and point to weakness in software stocks and rotation toward chip names. Some investors view the decline as disconnected from the companys growth and fundamentals, while bearish traders see continued selling pressure and further downside risk.

Keeta (KTA) is a cryptocurrency launched in 2025. Keeta has a current supply of 1,000,000,000 with 628,961,319.40126972 in circulation. The last known price of Keeta is 0.05762589 USD and is down -3.01 over the last 24 hours. It is currently trading on 112 active market(s) with $573,273.62 traded over the last 24 hours. More information can be found at https://keeta.com/.

Keeta

Discussion centers on Keetas planned payment and tokenization rollout, with traders speculatingwithout confirmationthat Google Clouds GCUL/CME effort could be a major partner, alongside the ASK Group/UAE and Visa-related initiatives. Bulls view these developments as potential adoption catalysts, while skeptics point to persistent selling and limited on-chain usage and question whether the partnerships will translate into token demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?

NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema

Equity

Nektar Therapeutics has multiple near-term catalysts in place, some expected as early as this month.


Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity

Shah Capital currently owns 11.8 million shares or 7.2% of Novavax.


MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside

Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares.


Capricor Stock Rises Pre-Market Over Fresh Hopes Of Deramiocel Approval In Treating Genetic Disorder

The company announced on Thursday that it held a meeting with the agency and plans to submit data from its HOPE-3 clinical trial as part of its current application.


iShares Trust - iShares MSCI USA Small-Cap ETF

Neutral Sentiment

<ul class="summary-bullets"><li>The company plans to begin its global late-stage program in moderate-to-severe atopic dermatitis by the end of July 2026.</li><li>In alopecia areata, a condition that causes hair loss, Nektar reported positive results from its mid-stage study in April 2026.</li><li>In the second half of 2026, Nektar also plans to present more data from its mid-stage eczema study, particularly how well improvements are sustained on lowered dosing.</li></ul><p>Shares of Nektar Therapeutics (NKTR) jumped 10% on Thursday as investors await updates on its lead candidate, rezpegaldesleukin, being developed for autoimmune and inflammatory diseases.</p><p>The company has multiple near-term catalysts in place, some expected as early as this month. The stock posted its best day since April on Thursday. &nbsp; &nbsp;</p><h2 class="st-heading-2">NKTR’s Atopic Dermatitis Program</h2><p>The company plans to begin its global late-stage program in moderate-to-severe atopic dermatitis by the end of July 2026. The studies will test a specific dose given every two weeks for the first six months, followed by less frequent maintenance doses. They will include both patients who have never tried biologic medicines and those who have already used them. The goal is to gather the data needed for regulatory approval, with the first results expected around mid-2028.</p><h2 class="st-heading-2">Progress In Alopecia Areata</h2><p>In alopecia areata, a condition that causes hair loss, Nektar reported positive results from its mid-stage study in April 2026. These findings showed stronger responses in patients with severe disease. The company then said that it plans to meet with the FDA in the second quarter of 2026 to discuss plans for larger late-stage trials. Additional data from patients who stopped treatment will be released in the fourth quarter of this year.</p><h2 class="st-heading-2">Other Catalysts</h2><p>A longer-term update showing results from patients one year after they stopped taking the drug in the eczema study is expected in the first quarter of 2027. This could indicate whether the treatment provides lasting benefits even after therapy ends.</p><p>In the second half of 2026, Nektar also plans to present more data from its mid-stage eczema study, particularly how well the improvements are sustained on lowered dosing, and begin an early study in at least one new disease area beyond atopic dermatitis, alopecia areata, and Type 1 diabetes.</p><p>Nektar ended the first quarter of 2026 with more than one billion dollars in cash and investments after a public offering. This strong financial position gives the company runway well into 2028 to advance its lead drug without needing immediate new funding, it previously said.</p><h2 class="st-heading-2">How Did NKTR Retail Traders React?</h2><p>On Stocktwits, retail sentiment around NKTR stock jumped from 'bearish' to 'bullish' territory over the past 24 hours, while message volume stayed at 'high' levels.</p><p>A Stocktwits user opined that momentum is building in NKTR stock.</p><p><stembedurl>https://www.stocktwits.com/FibonacciFortress/message/658228663</stembedurl></p><p>Another refuted the opinion, saying that there have not been many announcements from the company in recent weeks. “Quiet tape, fading catalysts, cold momentum,” they wrote.&nbsp;</p><p><stembedurl>https://www.stocktwits.com/FutureBulls/message/658197825</stembedurl></p><p><a href="https://stocktwits.com/symbol/NKTR">NKTR stock</a> has gained 68% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/biib-stock-ends-higher-why-this-strategist-picks-biogen-over-other-biotech-peers/cZm7GYQR7jB">BIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peers</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, on October 29, 2018. (Photo by Smith Collection/Gado/Getty Images)

Nektar Therapeutics has multiple near-term catalysts in place, some expected as early as this month.

Feed

News

Sentiment

Fundamentals

Info

ISCB iShares Morningstar Small-Cap ETF

Fundamentals

Latest ISCB News